Scholarly Index
Guang‐Yan Yu
Eli Lilly (United States); 5,372 total citations; 296 total publications; best world rank #131
Eli Lilly (United States)
5,372Total citations
296Total publications
41H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Salivary Gland Tumors Diagnosis and Treatment | Lifetime | 283 | US 145 | 98.14 |
| Oral and Maxillofacial Pathology | Lifetime | 399 | US 155 | 97.96 |
| Ear and Head Tumors | Lifetime | 260 | US 152 | 97.28 |
| Salivary Gland Disorders and Functions | Lifetime | 508 | US 167 | 94.95 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 358 | US 83 | 90.39 |
| Salivary Gland Disorders and Functions | 2021-2025 | 131 | US 15 | 91.34 |
| Salivary Gland Tumors Diagnosis and Treatment | 2021-2025 | 313 | US 75 | 87.13 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 162 | US 31 | 76.92 |
| Barrier Structure and Function Studies | 2021-2025 | 379 | US 104 | 65.51 |
| Connexins and lens biology | 2021-2025 | 863 | US 230 | 46.86 |